SCHEMBL5365504

SCHEMBL5365504

COC(=O)c1cc(Cl)ccc1Cc1cccc(Cl)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.53
PDE3B Q13370 1/20 0.50
PDE3A Q14432 1/20 0.50
MAPT P10636 5/20 0.49
MAPK1 P28482 1/20 0.49
ABL1 P00519 1/20 0.48
MAOB P27338 1/20 0.46
SLC6A4 P31645 1/20 0.46
SLC6A3 Q01959 1/20 0.46
PLA2G2A P14555 1/20 0.45
MEN1 O00255 1/20 0.45
LMNA P02545 1/20 0.45
HTT P42858 1/20 0.45
KMT2A Q03164 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
POLB P06746 1/20 0.45
APEX1 P27695 1/20 0.44
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5366100 0.89 KDM4E (0.47) HSP90AA1MAPK1ABL1MAOBPLA2G2A
SCHEMBL5367116 0.82 HCAR2 (0.50) PDE3BPDE3AMAPTMAPK1MEN1
SCHEMBL10174510 0.80 ABL1 (0.57) MAPK1ABL1SLC6A4SLC6A3PLA2G2A
SCHEMBL5361496 0.80 PTGER4 (0.66) PTGER4
SCHEMBL23040976 0.79 CYP4F2 (0.51) HSP90AA1MAOBPLA2G2AALDH1A1HPGD
SCHEMBL4447411 0.79 LMNA (0.46) HSP90AA1PDE3BPDE3AMAPTMAOB
SCHEMBL30692045 0.79 CYP4F2 (0.51) HSP90AA1MAOBPLA2G2AALDH1A1HPGD
SCHEMBL3981318 0.78 NR4A2 (0.52) ABL1MAOBKDM4E
SCHEMBL17398360 0.78 HSP90AA1 (0.51) HSP90AA1PDE3BPDE3AMAPTMAPK1
SCHEMBL3813996 0.78 MRGPRX4 (0.59) MAPTMAOBLMNAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663979-B1 PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS RAQUALIA PHARMA INC (JP) 2013-10-09 EP disclosed
US-7238714-B2 Aryl or heteroaryl amide compounds PFIZER JAPAN, INC. (JP) 2007-07-03 US disclosed
EP-1663979-A1 PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS PFIZER INC. (US) 2006-06-07 EP disclosed
US-20050065188-A1 Aryl or heteroaryl amide compounds ASKAT INC. (JP) 2005-03-24 US disclosed
WO-2005021508-A1 PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS PFIZER INC. (US) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065188-A1 Aryl or heteroaryl amide compounds HRH2, PTGER1, LTB4R2 HSP90AA1 2172/4885PDE3B 978/4885PDE3A 1414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.